Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors

ABSTRACT: Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors

PROVIDER: PRJNA390993 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5683170_1.fastq.gz	Fastqsanger.gz
	SRR5683170_2.fastq.gz	Fastqsanger.gz
	SRR5683171_1.fastq.gz	Fastqsanger.gz
	SRR5683171_2.fastq.gz	Fastqsanger.gz
	SRR5683172_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors [EPIC methylation]

Project description:Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, whether this is sufficient to drive cellular transformation in the absence of genetic mutations is not clear. To investigate this question, we use a CRISPR/dCas9 based epigenetic editing tool, where an inactive form of Cas9 is fused to DNMT3A and its regulator DNMT3L. Using this system, we show simultaneous de novo DNA methylation of genes commonly methylated in cancer, CDKN2A, RASSF1, HIC1 and PTEN in primary myoepithelial cells isolated from healthy human breast tissue. We find that promoter methylation is maintained in this system, even in the absence of the fusion construct and results in sustained repression of CDKN2A and RASSF1 transcripts which prevents cells from entering senescence. The phenotype is associated with retuned expression of a subset of genes to levels in early passage cells; however, the outgrowing myoepithelial cells are not immortal but proliferate for 25-30 population doublings before cell cycle arrest. Finally, we show that the key driver of this phenotype is repression of CDKN2A transcript p16, but prolonged proliferation is enhanced by combined hypermethylation and repression of both CDKN2A transcripts p16 and p14. This work demonstrates that hit-and-run epigenetic events can prevent senescence entry, a potential first step in the disease process.

2017-08-07 | GSE100184 | GEO

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors [RNA-seq]

Project description:Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, whether this is sufficient to drive cellular transformation in the absence of genetic mutations is not clear. To investigate this question, we use a CRISPR/dCas9 based epigenetic editing tool, where an inactive form of Cas9 is fused to DNMT3A and its regulator DNMT3L. Using this system, we show simultaneous de novo DNA methylation of genes commonly methylated in cancer, CDKN2A, RASSF1, HIC1 and PTEN in primary myoepithelial cells isolated from healthy human breast tissue. We find that promoter methylation is maintained in this system, even in the absence of the fusion construct and results in sustained repression of CDKN2A and RASSF1 transcripts which prevents cells from entering senescence. The phenotype is associated with retuned expression of a subset of genes to levels in early passage cells; however, the outgrowing myoepithelial cells are not immortal but proliferate for 18-20 population doublings before cell cycle arrest. Finally, we show that the key driver of this phenotype is repression of CDKN2A transcript p16, but prolonged proliferation is enhanced by combined hypermethylation and repression of both CDKN2A transcripts p16 and p14. This work demonstrates that hit-and-run epigenetic events can prevent senescence entry, a potential first step in the disease process.

2017-08-07 | GSE100027 | GEO

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors [EPIC methylation 2]

2017-08-07 | GSE100208 | GEO

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors.

Project description:Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, whether this is sufficient to drive cellular transformation is not clear. To investigate this question, we use a CRISPR-dCas9 epigenetic editing tool, where an inactive form of Cas9 is fused to DNA methyltransferase effectors. Using this system, here we show simultaneous de novo DNA methylation of genes commonly methylated in cancer, CDKN2A, RASSF1, HIC1 and PTEN in primary breast cells isolated from healthy human breast tissue. We find that promoter methylation is maintained in this system, even in the absence of the fusion construct, and this prevents cells from engaging senescence arrest. Our data show that the key driver of this phenotype is repression of CDKN2A transcript p16 where myoepithelial cells harbour cancer-like gene expression but do not exhibit anchorage-independent growth. This work demonstrates that hit-and-run epigenetic events can prevent senescence entry, which may facilitate tumour initiation.

| S-EPMC5684409 | biostudies-literature

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-08-07 | GSE100209 | GEO

Homo sapiens

Project description:Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors [EPIC methylation]

| PRJNA390989 | ENA

Homo sapiens

Project description:Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors [RNA-seq]

| PRJNA390528 | ENA

Homo sapiens

Project description:Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors [EPIC methylation 2]

| PRJNA390992 | ENA

Durable and efficient gene silencing in vivo by hit-and-run epigenome editing

Project description:Durable and efficient gene silencing in vivo by hit-and-run epigenome editing

| PRJNA939164 | ENA

Durable and efficient gene silencing in vivo by hit-and-run epigenome editing [RNAseq_2]

Project description:Durable and efficient gene silencing in vivo by hit-and-run epigenome editing [RNAseq_2]

| PRJNA1005918 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data